Premium Nahrungsergänzungsmittel | artgerecht

Sugammadex: Mechanism, Dosage & Clinical Use

Sugammadex is a medication used to reverse neuromuscular blockade after anaesthesia. It selectively binds muscle relaxants, enabling rapid recovery of muscle function.

Regular tips about health Regular tips about health

Things worth knowing about "Sugammadex"

Sugammadex is a medication used to reverse neuromuscular blockade after anaesthesia. It selectively binds muscle relaxants, enabling rapid recovery of muscle function.

What is Sugammadex?

Sugammadex (brand name: Bridion®) is a selective reversal agent used in anaesthesia to counteract the effects of certain neuromuscular blocking agents. It belongs to the class of modified gamma-cyclodextrins and was specifically designed to inactivate the muscle relaxants rocuronium and vecuronium. Sugammadex received approval in Europe in 2008 and in the United States in 2015.

Mechanism of Action

Unlike conventional reversal agents such as neostigmine, sugammadex does not act through the nervous system. Instead, it works via a unique encapsulation mechanism. The molecule surrounds the relaxant molecule like a molecular cage:

Sugammadex forms a highly stable 1:1 complex with rocuronium or vecuronium.
This binding inactivates the relaxant in the blood plasma, preventing it from reaching the neuromuscular junction.
Muscle contraction is rapidly restored without affecting the cholinergic system.
The complex is predominantly excreted unchanged via the kidneys.

Indications

Sugammadex is used in the following clinical situations:

Routine reversal of deep, moderate, or shallow neuromuscular blockade following surgery.
Emergency decurarisation in cases of unexpected difficult intubation or life-threatening situations (e.g. the "cannot intubate, cannot oxygenate" scenario).
Rapid reversal of deep rocuronium-induced blockade within minutes.

Dosage

The dosage of sugammadex depends on the depth of neuromuscular blockade and is typically calculated based on the patient's body weight:

Shallow blockade (T2 recovery present): 2 mg/kg body weight i.v.
Deep blockade (1-2 PTC): 4 mg/kg body weight i.v.
Immediate reversal of rocuronium blockade (3 minutes after bolus): 16 mg/kg body weight i.v.

Administration is given as a rapid intravenous bolus injection.

Side Effects

Sugammadex is generally well tolerated. Possible side effects include:

Common: Pain, tingling or burning at the injection site, bradycardia (slowed heart rate), altered sense of taste.
Rare: Hypersensitivity reactions, including anaphylaxis (severe allergic reaction) -- the medical team is prepared to manage this.
Very rare: Recurarisation (recurrence of neuromuscular block), particularly with insufficient dosing.

Interactions and Contraindications

Sugammadex may interact with various medications:

Hormonal contraceptives: Sugammadex may reduce the efficacy of oral contraceptives. Female patients should use an additional contraceptive method for 7 days following administration.
Toremifene, fusidic acid: May reduce the binding of sugammadex to rocuronium.
In cases of severe renal impairment (GFR < 30 ml/min), use is not recommended as excretion of the complex may be impaired.

Advantages Over Conventional Reversal Agents

Compared to the previously used neostigmine (a cholinesterase inhibitor), sugammadex offers several clinical advantages:

Faster and more complete antagonisation, even of deep blockades.
No need for concurrent administration of atropine to prevent bradycardia.
No cholinergic side effects such as excessive salivation or intestinal cramps.
Effective even at deep levels of neuromuscular blockade where neostigmine fails.

References

Bom A. et al. - A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angewandte Chemie International Edition, 2002; 41(2): 266-270.
European Medicines Agency (EMA) - Bridion (sugammadex) - Summary of Product Characteristics. EMA, 2008. Available at: https://www.ema.europa.eu
Fuchs-Buder T. et al. - Good clinical research practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents II. European Journal of Anaesthesiology, 2007; 24(12): 1-12.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.